Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended ...
Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million 2025 ...
News-Medical.Net on MSN
How somatic mutations shape disease and reveal new drug targets
By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...
The new report "Hematologic Malignancies Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast 2024–2032" has been added to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results